Lymph node metastasis in breast cancer: Common prognostic markers lack predictive value

Annals of Surgical Oncology

Volumn 5, Issue 7, 1998, Pages 613-619

  Velanovich, Vic ^a   Szymanski, Wanda ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Breast cancer; Lymph node metastases; Prognostic markers

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; TUMOR VOLUME;

EID: 0031754633     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303831     Document Type: Article

References (31)

1. Ruffin WK, Stacey-Clear A, Younger J, Hoover HC, Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245-51.
2. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
3. Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217-9.
4. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagani P. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer 1994;73:664-7.
5. Reger V, Beito G, Jolly PC. Factors affecting the incidence of lymph node metastases in small cancers of the breast. Am J Surg 1989;157:501-2.
6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
7. Dowlatshahi K, Snider HC, Kim R. Axillary node status in nonpalpable breast cancer. Ann Surg Oncol 1995;2:424-8.
8. Seidman JD, Schnoper LA, Aisner SC. Relationship of the size of invasive carcinoma to axillary lymph node metastasis. Cancer 1995;75:65-71.
9. Whitten TM, Fraser HR, Christensen WN, Turk PS. Axillary lymph node metastasis in stage T1a breast cancer: a pathologic review of 82 patients. Am Surg 1997;63:144-9.
10. Cady B. Traditional and future management of nonpalpable breast cancer. Am Surg 1997;63:55-8.
11. Velanovich V. Axillary lymph node dissection for breast cancer: a decision analysis of T1 lesions. Ann Surg Oncol 1998;5:131-9.
12. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
13. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
14. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-8.
15. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer: a multivariate analysis. Cancer 1994;73:350-3.
16. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
17. Wood WC. Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 1994;18:39-44.
18. Hortobagyi GN, Bazdur AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995;45:199-226.
19. Velanovich V, Szymanski W. Quality of life in breast cancer patients with lymphedema. Surg Forum 1997;48:605-6.
20. Giuliano AE, Barth AM, Spivack B, Beitsch PD. Incidence of predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996;183:185-9.
21. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997;79:1918-22.
22. Tolmos J, Khalkhali I, Vargas H, et al. Detection of axillary lymph node metastasis of breast carcinoma with technetium-99m sestamibi scintimammography. Am Surg 1997;63:850-3.
23. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-44.
24. Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691-700.
25. Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg 1997;226:279-87.
26. Velanovich V. Biologic tumor markers, lymph node status, and decisions about adjuvant chemotherapy for breast cancer. Am Surg 1997;63:330-3.
27. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol 1996;14:3105-11.
28. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312;674-81.
29. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985;5:17-21.
30. Cabanes PA, Salmon RJ, Vicoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992;339:1245-8.
31. White RE, Vezeridis MP, Konstadoulakis M, et al. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg 1996;183:575-82.